Ongoing treatment(s)-Biological therapy Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Biological therapy Posts on Medivizor

Clarithromycin administered daily reduces the skin-related side effects associated with panitumumab treatment for metastatic colorectal cancer.

Clarithromycin administered daily reduces the skin-related side effects associated with panitumumab treatment for metastatic colorectal cancer.

Posted by on Sep 5, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of preventative antibiotic treatment with clarithromycin (Biaxin) to prevent skin-related side effects associated with panitumumab (Vectibix) treatment for patients with metastatic colorectal cancer (mCRC). The data showed that clarithromycin administered daily along with a simple...

Read More

Evaluating the final effectiveness and safety outcomes of neratinib in patients with early stage HER2+/HR+ breast cancer.

Evaluating the final effectiveness and safety outcomes of neratinib in patients with early stage HER2+/HR+ breast cancer.

Posted by on Apr 4, 2021 in Breast cancer | 0 comments

In a nutshell This study reported the final effectiveness and safety outcomes of neratinib treatment in patients with early-stage HER2+/HR+ breast cancer. The data showed that neratinib significantly improved invasive disease-free survival in these patients who initiated treatment within 1 year of trastuzumab-based therapy. Some background...

Read More

How does durvalumab impact the treatment of unresectable stage III non-small cell lung cancer based on previous treatment?

How does durvalumab impact the treatment of unresectable stage III non-small cell lung cancer based on previous treatment?

Posted by on Mar 14, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at the outcomes of durvalumab (Imfinzi) in patients with unresectable (cannot be surgically removed) stage 3 non-small cell lung cancer (NSCLC) who received different combinations of chemoradiotherapy (CRT) previously. The authors found that the use of durvalumab improved survival in all patients previously treated...

Read More

Nivolumab improves survival in patients with non-small cell lung cancer in the long-term.

Nivolumab improves survival in patients with non-small cell lung cancer in the long-term.

Posted by on Feb 28, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at 5-year outcomes of patients with previously treated advanced non-small-cell lung cancer (NSCLC) taking nivolumab (Opdivo) compared to docetaxel (Taxotere). The authors found that nivolumab continued to improve the outcomes of these patients after 5 years. Some background NSCLC is the most common...

Read More

Is heart monitoring needed in patients with HER2-positive metastatic breast cancer using trastuzumab?

Is heart monitoring needed in patients with HER2-positive metastatic breast cancer using trastuzumab?

Posted by on Feb 20, 2021 in Breast cancer | 0 comments

In a nutshell This article looked at the occurrence of heart-related side effects in patients with HER2-positive metastatic breast cancer (mBC) receiving trastuzumab (Herceptin). The authors found that non-smoking patients with a good heart function before receiving treatment have a low risk of heart toxicity (HT) after 4 years...

Read More

Can tumor mutation burden be used as a predictive biomarker to immune checkpoint inhibitors for non-small cell lung cancer?

Can tumor mutation burden be used as a predictive biomarker to immune checkpoint inhibitors for non-small cell lung cancer?

Posted by on Feb 14, 2021 in Lung cancer | 0 comments

In a nutshell This article looked at the use of tumor mutation burden (TMB) to predict response to immune checkpoint inhibitor (ICI) therapy in patients with non-small cell lung cancer (NSCLC). The authors found that TMB is a promising biomarker that can predict the effectiveness of ICI therapy in advanced NSCLC.  Some background NSCLC...

Read More

Evaluating the effectiveness and safety of bevacizumab biosimilar in patients with metastatic colorectal cancer

Evaluating the effectiveness and safety of bevacizumab biosimilar in patients with metastatic colorectal cancer

Posted by on May 17, 2020 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of bevacizumab biosimilar (BE1040V) to the reference drug (Avastin) in the treatment of patients with metastatic colorectal cancer (mCRC). Researchers suggested that the effectiveness and safety of the biosimilar were similar to the reference drug bevacizumab. Some...

Read More

Can antibiotics and proton pump inhibitors alter the effectiveness of treatment for patients with non-small cell lung cancer?

Posted by on Apr 21, 2020 in Lung cancer | 0 comments

In a nutshell This study examined the effects of antibiotics or proton pump inhibitor (PPI) drugs on treatment for patients with non-small cell lung cancer (NSCLC). The authors found that both antibiotics and PPIs reduced the effectiveness of biological therapy but not chemotherapy. Some background Not all patients with NSCLC respond to...

Read More

Managing joint and muscle pain in patients with chronic lymphocytic leukemia treated with ibrutinib

Posted by on Apr 14, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the occurrence and risks of joint/muscle pain as side effects of ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL). The authors found that 36% of patients developed joint/muscle pain and most were younger and females receiving ibrutinib as the first treatment. Some background Ibrutinib kills...

Read More

What gut-related side effects do immunotherapy drugs and chemotherapy cause patients with cancer?

Posted by on Apr 14, 2020 in Lung cancer | 0 comments

In a nutshell This study examined if certain immunotherapy drugs increased the risk of developing side effects in the gut in patients with cancer also receiving chemotherapy. The results showed that immunotherapy drugs increased the risks of developing gut-related side effects compared to chemotherapy alone. Some background Immunotherapy drugs that...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2021 Medivizor